Outocome of metastatic renal cell carcinoma patients : (رقم التسجيلة. 178260)
[ عرض عادي ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05528namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20260215103614.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 260208s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99461 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.99461 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.19.04.M.Sc.2025.Su.O |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Suzy Abdo Samy Abdo, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Outocome of metastatic renal cell carcinoma patients : |
| Remainder of title | a five-year retrospective single institution experience / |
| Statement of responsibility, etc. | by Suzy Abdo Samy Abdo ; Supervision Dr. Hanan Ezzat Shafik, Dr. Yahia Mahmoud Ismail, Dr. Abd El-Maksoud Mohammed Abd El-Maksoud. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | نتائج مرضي سرطان الخلايا الكلويه النقيلي : |
| Remainder of title | تجربه موسسه واحده باثر رجعي للمده خمس سنوات / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 93 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 84-93. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Background: Metastatic renal cell carcinoma (mRCC) remains a major <br/>clinical challenge with a poor long-term prognosis. Advances in targeted <br/>therapies, including vascular endothelial growth factor (VEGF) inhibitors <br/>like sunitinib and pazopanib, have been used as first-line treatment <br/>options. However, real-world evidence on outcomes in specific <br/>populations remains limited. <br/>Objective: This study aimed to evaluate the overall survival (OS) and <br/>progression-free survival (PFS) in mRCC patients treated with sunitinib <br/>or pazopanib as first-line therapy at the National Cancer Institute, Cairo <br/>University, between January 2018 and December 2022. <br/>Methods: A retrospective cohort analysis was conducted on 84 mRCC <br/>patients aged 24–74 years old. Patients were stratified based on clinical <br/>presentation, histological subtype, International Metastatic Renal Cell <br/>Carcinoma Database Consortium (IMDC) risk scores, and initial <br/>treatment. Kaplan-Meier analysis was used to estimate OS and PFS, <br/>while Cox regression identified predictors of these outcomes. <br/>Results: Intermediate IMDC risk was the most prevalent, 52.4%. <br/>Sunitinib was administered to 73.8% and pazopanib to 26.2%. Median <br/>OS and PFS were 21 and 8 months, respectively. The 5-year OS and PFS <br/>rates were 26.2% and 9.5%, respectively. Early treatment initiation (≤1 <br/>year), poor performance status II/III (PS), high neutrophil-lymphocyte <br/>ratio (NLR) and Platelet-lymphocyte ratio (PLR), and poor IMDC risk <br/>were significantly associated with reduced survival. No significant OS or <br/>PFS difference was observed between sunitinib and pazopanib. <br/>Conclusion: This study highlighted the prognostic importance of timely <br/>treatment initiation, risk stratification, and inflammatory markers in <br/>mRCC. Although sunitinib and pazopanib showed comparable efficacy, <br/>individual patient characteristics critically influenced the outcomes. <br/>These findings support the need for personalized treatment strategies in <br/>mRCC. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | كان هذا تحليلًا استعاديًا لمدة خمس سنوات شمل ٨٤ مريضًا بسرطان الكلى النقيلي المتقدم في الفترة من عام ٢٠١٨ حتى ٢٠٢٢، لتقييم فعالية علاجات الخط الأول وهما السونيتينيب والبازوبانيب على معدل البقاء الكلي والبقاء دون تقدم المرض، بالإضافة إلى العوامل التنبؤية المرتبطة بالبقاء.<br/>الخلفيه العلميه و الهدف من الدراسه:<br/>تبرز هذه الدراسة أن توقيت بدء العلاج، ودرجة الخطورة وفق تصنيف رابطة بيانات سرطان الكلى النقيلي، والعلامات الالتهابية مثل نسبة العدلات إلى الخلايا اللمفاوية، ونسبة الصفائح إلى الخلايا اللمفاوية، تؤثر بشكل كبير على نتائج البقاء.<br/>طرق البحث <br/>كان متوسط البقاء الكلي ٢١ شهرًا، مع معدل بقاء لمدة خمس سنوات بلغ ٢٦٫٢٪، بينما بلغ معدل البقاء دون تقدم المرض ٩٫٥٪.<br/>النتائج و الاستنتاج <br/>متوسط البقاء الكلي: ٢١ شهرًا (فترة الثقة: من ١٨ إلى ٢١ شهرًا)<br/>نسبة البقاء بعد خمس سنوات: ٢٦٫٢٪<br/>نسبة البقاء دون تقدم المرض: ٩٫٥٪ |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Renal cell carcinoma |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | سرطان الكلى النقلي |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | renal cell carcinoma |
| -- | overall survival |
| -- | progression free survival |
| -- | suitnib and pazobenib |
| -- | سرطان الكلي |
| -- | سرطان الكلى النقلي |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hanan Ezzat Shafik |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yahia Mahmoud Ismail |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Abd El-Maksoud Mohammed Abd El-Maksoud |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Hanan Ezzat Shafik |
| -- | Yahia Mahmoud Ismail |
| -- | Abd El-Maksoud Mohammed Abd El-Maksoud |
| Universities | Cairo University |
| Faculties | Faculty of Medicine |
| Department | Department of Medical Oncology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 08.02.2026 | 93309 | Cai01.19.04.M.Sc.2025.Su.O | 01010110093309000 | 08.02.2026 | 08.02.2026 | Thesis |